- Category
- Medium (2022-23)
- Udyam number
- UDYAM-TS-02-0002373

About Credo Life Sciences Private Limited
Data last updated:
Credo Life Sciences Private Limited is a private limited company based in Hyderabad, Telangana, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 03 July 2014 and has been in existence for over 12 years.
The company is registered with the Registrar of Companies (ROC), Hyderabad, under CIN U24232TG2014PTC112849. Its GSTIN is 36AAFCC7068Q1ZX (Telangana). The company holds 2 GST registrations, of which 1 is active.
The company has an authorised share capital of ₹15.5 Cr and a paid-up capital of ₹13.5 Cr. It is led by directors including Siva Rama Prasad Aluru (Managing Director) and Kandru Madhavarao.
Its last annual general meeting (AGM) was held on 30 September 2024, and its latest financial statements are for the year ended 31 March 2024. The registered office is at Hyderabad, Telangana.
As per the financials filed for FY 2024, the company reported a revenue of ₹100.47 Cr, a growth of 22% compared to the previous year. For the same year it recorded a net profit of ₹6.53 Cr (net margin 6.5%) and EBITDA of ₹14.65 Cr (EBITDA margin 14.6%). Revenue has grown at a compounded annual rate (CAGR) of 26% over three years and 31% over five years.
The company has about 193 employees on its provident fund (EPFO) records.
The company is associated with 1 brand: Credo Life. As per MCA filings, the company has open charges of ₹32.48 Cr on record. Court records list 1 case involving the company, including 1 filed against it. The company has 6 deals on record (3 funding rounds, 2 secondary share transfers, 1 rights issue), with disclosed funding of ₹11.39 Cr; the latest was in January 2023. Its 7 peer companies in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 4 larger and 3 smaller; the largest is Nabros Pharma Private Limited with revenue of ₹101.03 Cr.
Credo Life Sciences Private Limited is registered as a medium enterprise under the Udyam registration framework (Reg. No. UDYAM-TS-02-0002373). The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website credolife.in.
Company details
CIN history
Credo Life Sciences has one previous CIN (Corporate Identification Number): U24232AP2014PTC094778. The current CIN is U24232TG2014PTC112849, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| U24232TG2014PTC112849 | Current |
| U24232AP2014PTC094778 | Previous |
Recognitions & Rankings of Credo Life Sciences
Contact details
Credo Life Sciences Private Limited's registered office is in Hyderabad, Telangana. Its website is credolife.in. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Registered AddressFlat No. 1101 Vasavi Sky City. 11th Floor Tower – 1, Telecom Nagar Gachibowli, Hyderabad, Telangana, India – 500081
- IndustryPharma, Drug Formulation & Development
To see the full contact details of Credo Life Sciences Private Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Brands
Credo Life Sciences operates one associated brand: Credo Life. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Supplies specialized pellets and taste-masking granules for global markets. | credolife.in |
Business activity
The main business activity of Credo Life Sciences is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of Credo Life Sciences Private Limited, buy the company report.
Financials of Credo Life Sciences Private Limited
FY 2024 filings availableCredo Life Sciences Private Limited reported revenue of ₹100.47 Cr (up 22% YoY) for FY 2024.
Compounded Annual Growth Rate (CAGR)
Revenue has grown at a compounded annual rate (CAGR) of 31% over five years, including 22% growth in the latest year. EBITDA rose 68% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | ₹100.47 Cr | ||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹14.65 Cr | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹6.53 Cr | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 14.6% | ||||
| Net Profit Margin | 6.5% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Credo Life Sciences Private Limited, buy the company report.
Board of directors of Credo Life Sciences Private Limited
Credo Life Sciences has 3 current directors and 3 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Kandru Madhavarao Also directs: Credo Pharma Private Limited | Director | 01 Apr 2015 | 11 Years 7 Months | Current |
| Siva Rama Prasad Aluru Also directs: Auctus Life Sciences LLP, Credo Pharma Private Limited | Managing Director | 03 Jul 2014 | 12 Years 4 Months | Current |
| Aluru Vamsi Krishna Also directs: Auctus Life Sciences LLP, Credo Pharma Private Limited | Director | 03 Jul 2014 | 12 Years 4 Months | Current |
Peer comparison
Credo Life Sciences Private Limited is compared with the 7 companies closest to it by revenue in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Nabros Pharma Private Limited | ₹101.03 Cr (FY 2025) | 6.0% | Ahmedabad, Gujarat, India | |||
| Instapill Private Limited | ₹100.92 Cr (FY 2025) | 11.0% | Bangalore, Karnataka, India | |||
| Sotac Pharmaceuticals Limited | ₹100.88 Cr (FY 2025) | -3.0% | Sanand, Gujarat, India | |||
| Lake Chemicals Private Limited | ₹100.59 Cr (FY 2025) | -5.0% | Bangalore, Karnataka, India | |||
| Credo Life Sciences Private Limitedthis company | ₹100.47 Cr (FY 2024) | ₹6.53 Cr | 6.5% | 22.0% | 193 | Hyderabad, Telangana, India |
| Consern Pharma Limited | ₹100.37 Cr (FY 2025) | -2.0% | Ludhiana, Punjab, India | |||
| Medibios Laboratories Limited | ₹100.12 Cr (FY 2023) | -2.0% | ||||
| Synokem Lifesciences Private Limited | ₹99.46 Cr (FY 2025) | 108.0% | New Delhi, Delhi, India |
To see the full peer comparison of Credo Life Sciences Private Limited, buy the company report.
Auditor
Credo Life Sciences Private Limited is audited by K. Nagaraju & Associates for the financial year 2024.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| K. Nagaraju & Associates | FY 2024 | 002270S |
Shareholding
The shareholding of Credo Life Sciences Private Limited is on record for 5 financial years, the latest being FY 2024, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
| Promoters | |||||
| Domestic institutional investors (DII) | |||||
| Foreign institutional investors (FII) | |||||
| Public | |||||
| Others |
To see the full shareholding pattern of Credo Life Sciences Private Limited, buy the company report.
Charges & borrowings
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 19 Feb 2025 | 101061800 | Indian Bank | ₹1.98 Cr | Open | |
| 18 Nov 2024 | 101010188 | Indian Bank | ₹2.15 Cr | Open | |
| 03 Jan 2023 | 100696697 | Hdfc Bank Limited | ₹35 Lakh | Open | |
| 31 Oct 2016 | 100068549 | Indian Bank | ₹28 Cr | Open |
To see the full charge records of Credo Life Sciences Private Limited, buy the company report.
Total charge records: 4 View all charges
Deals & funding
Credo Life Sciences Private Limited has 6 deals on record (3 funding rounds, 2 secondary share transfers, 1 rights issue), with disclosed funding of ₹11.39 Cr; the latest was in January 2023.
Deals on record (5 of 6)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Jan 2023 | Secondary share transfer | Undisclosed | Buyer: 3 individuals Seller: 3 individuals |
| Oct 2021 | Secondary share transfer | Undisclosed | Buyer: 2 individuals Seller: 3 individuals |
| Jun 2021 | Rights issue | ₹2 Cr | Investors: 2 individuals |
| Jun 2017 | Funding round | ₹2.5 Cr | Investors: 4 individuals |
| Jul 2016 | Funding round | ₹2.28 Cr | Investors: 4 individuals |
To see the full deal history of Credo Life Sciences Private Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Credo Life Sciences Private Limited has 1 court case on record: 1 filed against it. All case is disposed.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| High courts | 1 | 1 | 0 |
Cases on record (1 of 1)
| Court | Type of case | Party | Status |
|---|---|---|---|
| High Court for State of Telangana | Writ petition | Filed against the company | Disposed |
To see the full case history of Credo Life Sciences Private Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
Credit ratings & regulatory alerts
Credo Life Sciences Private Limited was last rated by Icra on 17 Feb 2022.
| Rating agency | Rated on | Rating |
|---|---|---|
| Icra | 17 Feb 2022 |
To see the full credit ratings and regulatory alerts of Credo Life Sciences Private Limited, buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Credo Life Sciences Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
Employees & EPFO
Credo Life Sciences Private Limited has a workforce of 193 employees on its EPFO records as of May 2026, across 1 active EPFO establishment.
Headcount by financial year
| Financial year | Employees (EPFO) |
|---|---|
| FY 2026-27 | 193 |
| FY 2025-26 | |
| FY 2024-25 | |
| FY 2023-24 | |
| FY 2022-23 | |
| FY 2021-22 | |
| FY 2020-21 | |
| FY 2019-20 | |
| FY 2018-19 | |
| FY 2017-18 | |
| FY 2016-17 |
To see the full employee and EPFO history of Credo Life Sciences Private Limited, buy the company report.
GST
Credo Life Sciences has 2 GST registrations: 1 active and 1 cancelled or inactive.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 36AAFCC7068Q1ZX | Telangana | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of Credo Life Sciences Private Limited, buy the company report.
Recent activity
Credo Life Sciences Private Limited has 6 board changes on record since 2014: 3 appointments and 3 cessations. The latest: Venkata Narayana Reddy Konda ceased to be Company Secretary on 06 Jul 2021.
2 earlier events are in the company report.
Frequently asked questions
Credo Life Sciences is an active private limited company based in Hyderabad, Telangana, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 03 July 2014 (12+ years old) and is registered under CIN U24232TG2014PTC112849.
Credo Life Sciences has 3 current directors:
- Siva Rama Prasad Aluru - Managing Director
- Kandru Madhavarao - Director
- Aluru Vamsi Krishna - Director
The latest financial statements of Credo Life Sciences on record with the MCA are for the year ended 31 March 2024. Its last annual general meeting was held on 30 September 2024. Year-wise statements from 2015 are in the company report.
The GSTIN of Credo Life Sciences is 36AAFCC7068Q1ZX, registered in Telangana. The company has 2 GST registrations in all, of which 1 is active and 1 is cancelled or inactive.
The CIN (Corporate Identification Number) of Credo Life Sciences is U24232TG2014PTC112849. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Credo Life Sciences has 1 court case on record: 1 filed against it.
Credo Life Sciences was incorporated on 03 July 2014, making it 12+ years old. It is registered with the Registrar of Companies, Hyderabad.
Credo Life Sciences has 6 deals on record (3 funding rounds, 2 secondary share transfers, 1 rights issue), with disclosed funding of ₹11.39 Cr; the latest was in January 2023.
The peers of Credo Life Sciences by revenue are Nabros Pharma Private Limited, Instapill Private Limited, Sotac Pharmaceuticals Limited, Lake Chemicals Private Limited, Consern Pharma Limited and 2 more, all in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).
Venkata Narayana Reddy Konda ceased to be Company Secretary on 06 Jul 2021. Kandru Madhavarao ceased to be Additional Director on 18 Sep 2015. Kandru Madhavarao was appointed as Director on 01 Apr 2015. Credo Life Sciences has 6 board changes on record in total.
Yes, Credo Life Sciences is registered as a medium enterprise under Udyam registration (number: UDYAM-TS-02-0002373).

